{{Drugbox
| IUPAC_name = ''N''-<nowiki/>{[(5''S'')-3-(2-fluoro-4&prime;-<nowiki/>{[(1''H''-1,2,3-triazol-5-ylmethyl)amino]methyl}biphenyl-4-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
| image = Radezolid.svg
| alt = Skeletal formula of radezolid

<!--Clinical data-->
| tradename =  
| legal_status = Investigational
| routes_of_administration = [[Intravenous therapy|Intravenous infusion]], oral

<!--Identifiers-->
| CAS_number = 869884-78-6
| ATC_prefix = none
| PubChem = 11224409
| ChemSpiderID = 9399462
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 53PC6LO35W
| ChEMBL = 455461

<!--Chemical data-->
| C=22 | H=23 | F=1 | N=6 | O=3 
| molecular_weight = 438.455 g/mol
| smiles = CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(c(c2)F)c3ccc(cc3)CNCc4cnn[nH]4
}}
'''Radezolid''' ([[International Nonproprietary Name|INN]], codenamed '''RX-1741''') is a novel [[oxazolidinone]] antibiotic being developed by [[Melinta Therapeutics]], Inc. for the treatment of bacterial acne.<ref name=Hartford2016>{{cite news|last1=Stearns|first1=John|title=Melinta Therapeutics takes aim at deadly drug-resistant bacteria|url=http://www.hartfordbusiness.com/article/20160801/PRINTEDITION/307289945/melinta-therapeutics-takes-aim-at-deadly-drug-resistant-bacteria|work=Hartford Business Journal|date=August 1, 2016}}</ref> 

== References ==
{{reflist}}

==Further reading==
*{{cite journal  |vauthors=Zhou J, Bhattacharjee A, Chen S, etal |title=Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics |journal=Bioorg. Med. Chem. Lett. |volume=18 |issue=23 |pages=6175–8 |date=December 2008 |pmid=18947996 |doi=10.1016/j.bmcl.2008.10.011}}
* {{cite journal  |vauthors=Skripkin E, McConnell TS, DeVito J, etal |title=Rχ-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance |journal=Antimicrob. Agents Chemother. |volume=52 |issue=10 |pages=3550–7 |date=October 2008 |pmid=18663023 |pmc=2565890 |doi=10.1128/AAC.01193-07}}
*{{cite journal |vauthors=Lawrence L, Danese P, DeVito J, Franceschi F, Sutcliffe J |title=In vitro activities of the Rχ-01 oxazolidinones against hospital and community pathogens |journal=Antimicrob. Agents Chemother. |volume=52 |issue=5 |pages=1653–62 |date=May 2008 |pmid=18316525 |pmc=2346622 |doi=10.1128/AAC.01383-07}}
*{{cite journal |vauthors=Hanselmann R, Job G, Johnson G, Lou R, Martynow JG, Reeve MM |title=Synthesis of an antibacterial compound containing a 1,4-substituted 1H-1,2,3-triazole- a scaleable alternative to the "click" reaction" |year=2009 |journal=Organic Process Research and Development |doi=10.1021/op900252a |volume=14 |pages=152–158}}
*{{cite journal |vauthors=Franceschi F, Duffy EM |title=Structure-based drug design meets the ribosome |journal=Biochem. Pharmacol. |volume=71 |issue=7 |pages=1016–25 |date=March 2006 |pmid=16443192 |doi=10.1016/j.bcp.2005.12.026}}
*{{cite journal |author=Ohlsen K |title=Novel antibiotics for the treatment of ''Staphylococcus aureus'' |journal=Expert Rev. Clin. Pharmacol. |volume=2 |issue=6 |pages=661–72 |date=November 2009 |doi=10.1586/ecp.09.26}}
{{refend}}



{{Protein synthesis inhibitor antibiotics}}

[[Category:Oxazolidinone antibiotics]]
[[Category:Triazoles]]
[[Category:Fluoroarenes]]
[[Category:Acetamides]]
[[Category:Biphenyls]]


{{antibiotic-stub}}